| Q32049879 | A review of budesonide inhalation suspension in the treatment of pediatric asthma |
| Q26776289 | A systematic review of predictive models for asthma development in children |
| Q41969395 | Accuracy of specific IgE in the prediction of asthma: development of a scoring formula for general practice |
| Q35225926 | Adrenal suppression: A practical guide to the screening and management of this under-recognized complication of inhaled corticosteroid therapy |
| Q33731149 | Airway remodeling and persistent airway obstruction in asthma |
| Q33751283 | Airway wall remodelling: does it occur and what does it mean? |
| Q51107848 | Association between candidate genes and lung function growth in Chinese asthmatic children. |
| Q36380810 | Association of glucocorticoid insensitivity with increased expression of glucocorticoid receptor beta |
| Q34150855 | Asthma and other recurrent wheezing disorders in children (chronic) |
| Q93501243 | Asthma and other wheezing disorders in children |
| Q37933500 | Asthma and the achievement gap among urban minority youth |
| Q55001076 | Asthma guidelines: invited commentaries. |
| Q91905180 | Asthma in children: mapping the literature by bibliometric analysis |
| Q91709906 | Asthma progression and mortality: the role of inhaled corticosteroids |
| Q39575274 | Asthma symptoms, morbidity, and antiinflammatory use in inner-city children |
| Q37180213 | Asthma therapies revisited: what have we learned? |
| Q41655810 | Asthma treatment and growth |
| Q53369314 | Asthma treatment in schoolchildren: lung function in different therapeutic groups. |
| Q43784447 | Asthma treatment with inhaled corticosteroids versus antileukotrienes: what exhaled nitric oxide studies do and do not tell us. |
| Q42620547 | Asthma trends. Optimal treatment includes inhaled steroids |
| Q33640272 | Asthma versus chronic obstructive pulmonary disease--exploring why 'reversibility versus irreversibility' is no longer an appropriate approach |
| Q33909166 | Beclomethasone for asthma in children: effects on linear growth |
| Q90247731 | Benefit:Risk Profile of Budesonide in Obstructive Airways Disease |
| Q93385050 | Biomarkers for Recurrent Wheezing and Asthma in Preschool Children |
| Q33210213 | Bone mineral status in children with cow milk allergy. |
| Q34339693 | Bronchial changes in untreated asthma |
| Q40498162 | Bronchial hyper-responsiveness predicts the development of mild clinical asthma within 2 yr in school children with hay-fever |
| Q44147928 | Budesonide aqueous nasal spray is an effective treatment in children with perennial allergic rhinitis, with an onset of action within 12 hours |
| Q34112928 | Budesonide inhalation suspension: a review of its use in infants, children and adults with inflammatory respiratory disorders |
| Q44161807 | Budesonide/formoterol in a single inhaler versus inhaled corticosteroids alone in the treatment of asthma |
| Q40996063 | Can steroids cause asthma to remit? |
| Q52137972 | Can we predict which wheezy infants will continue to wheeze? |
| Q73077367 | Childhood asthma and lung function in mid-adult life |
| Q34405467 | Childhood asthma surveillance using computerized billing records: a pilot study. |
| Q74810185 | Childhood asthma--all that wheezes is not inflammation |
| Q36647136 | Childhood asthma: breakthroughs and challenges |
| Q35536284 | Childhood factors associated with asthma remission after 30 year follow up. |
| Q34481341 | Choosing therapy for childhood asthma |
| Q33996589 | Clinical implications of inflammation in young children |
| Q74217126 | Clinical issues in paediatric asthma |
| Q39468637 | Clinical management of asthma in the 1990s. Current therapy and new directions. |
| Q34523871 | Combination therapy with inhaled long-acting beta2-agonists and inhaled corticosteroids: a paradigm shift in asthma management |
| Q41753582 | Comparable efficacy of administration with face mask or mouthpiece of nebulized budesonide inhalation suspension for infants and young children with persistent asthma |
| Q43584795 | Comparable efficacy of administration with face mask or mouthpiece of nebulized budesonide suspension for infants and young children with persistant asthma |
| Q44844973 | Compatibility of budesonide inhalation suspension with four nebulizing solutions |
| Q33977274 | Consequences of long-term inflammation. The natural history of asthma |
| Q73045331 | Corticosteroid treatment of asthma: now at the crossroads. Reply to Drs Seale and Donnelly |
| Q24564291 | Corticosteroid-resistant bronchial asthma is associated with increased c-fos expression in monocytes and T lymphocytes |
| Q33878221 | Corticosteroid-sparing options in the treatment of childhood asthma |
| Q80967152 | Cost-Effectiveness of Budesonide Controlled Ileal Release (CIR) Capsules as Maintenance Therapy versus No Maintenance Therapy for Ileocaecal Crohn's Disease in Sweden |
| Q51237797 | Cost-effectiveness of early intervention with once-daily budesonide in children with mild persistent asthma: results from the START study. |
| Q34631320 | Critical evaluation of prognostic factors in childhood asthma |
| Q46635740 | Daily inhaled corticosteroid treatment should not be prescribed for mild persistent asthma. Con. |
| Q36869140 | Daily versus as-needed inhaled corticosteroid for mild persistent asthma (The Helsinki early intervention childhood asthma study). |
| Q34341891 | Design and analytic considerations in determining the cost-effectiveness of early intervention in asthma from a multinational clinical trial. |
| Q64119322 | Determinants of airflow limitation in Danish adults - findings from the Health2006 cohort |
| Q34929535 | Diagnosing asthma in young children |
| Q47901753 | Differential diagnosis of IgE-mediated allergy in young children with wheezing or eczema symptoms using a single blood test |
| Q44058288 | Differential patterns of circulating adhesion molecules in children with bronchial asthma and acute bronchiolitis |
| Q34345371 | Do inhaled corticosteroids inhibit growth in children? |
| Q73028987 | Dose-response evaluation of the therapeutic index for inhaled budesonide in patients with mild-to-moderate asthma |
| Q37733515 | Early intervention for infantile and childhood asthma |
| Q44388200 | Early intervention with budesonide in mild persistent asthma: a randomised, double-blind trial |
| Q40804034 | Early treatment of asthma |
| Q74810191 | Early use of inhaled steroids in children with asthma |
| Q74810196 | Early use of inhaled steroids in children with asthma. Concluding comments |
| Q71810384 | Effect of Early vs Late Intervention With Inhaled Corticosteroids in Asthma |
| Q33760980 | Effect of asthma and its treatment on growth: four year follow up of cohort of children from general practices in Tayside, Scotland |
| Q71219839 | Effect of fluticasone on growth in children with asthma |
| Q33588408 | Effect of inhaled beclomethasone dipropionate and budesonide on growth in children with asthma |
| Q35047955 | Effect of inhaled corticosteroids on long-term growth in pediatric patients with asthma and allergic rhinitis |
| Q35076971 | Effects of childhood respiratory diseases on the anatomical and functional development of the respiratory system |
| Q83172082 | Effects of early intervention with inhaled sodium cromoglycate in childhood asthma |
| Q50851805 | Effects of inhaled corticosteroids and inhaled cromolyn sodium on urinary growth hormone excretion in asthmatic children. |
| Q74488906 | Effects of inhaled corticosteroids on growth |
| Q46694299 | Effects of inhaled corticosteroids on the consequences of asthma |
| Q44733659 | Effects of inhaled fluticasone propionate in children less than 2 years old with recurrent wheezing |
| Q34800047 | Effects of inhaled steroid treatment on serum eosinophilic cationic protein (ECP) and low affinity receptor for IgE (Fc epsilon RII/sCD23) in childhood bronchial asthma |
| Q35113146 | Effects of nasal corticosteroids on boosts of systemic allergen-specific IgE production induced by nasal allergen exposure |
| Q31394667 | Effects of several glucocorticosteroids and PDE4 inhibitors on increases in total lung eosinophil peroxidase (EPO) levels following either systemic or intratracheal administration in sephadex- or ovalbumin-induced inflammatory models |
| Q73255187 | Efficacy and safety of dry powder fluticasone propionate in children with persistent asthma |
| Q41728966 | Efficacy and safety of inhaled corticosteroids. New developments |
| Q43986529 | Efficacy and safety of inhaled steroid and cromone treatment in school-age children: a randomized pragmatic pilot study. |
| Q44054406 | Efficacy and safety of low-dose fluticasone propionate compared with zafirlukast in patients with persistent asthma |
| Q34786562 | Efficacy of budesonide in inhaled corticosteroid-naive patients and patients with mild persistent asthma |
| Q34738061 | Efficacy of budesonide in moderate to severe asthma |
| Q42608735 | Efficacy of once- and twice-daily administration of budesonide via Turbuhaler as initial therapy in patients with mild persistent asthma |
| Q73118634 | Efficacy of once-daily versus twice-daily administration of budesonide by Turbuhaler(R) in children with stable asthma |
| Q48361826 | Establishing a therapeutic index for the inhaled corticosteroids: part II. Comparisons of systemic activity and safety among different inhaled corticosteroids |
| Q47221849 | Experience with quantitative IgE antibody analysis in relation to allergic disease within the BAMSE birth cohort--towards an improved diagnostic process |
| Q88727960 | Exploding asthma and ADHD caseloads: The role of medicaid managed care |
| Q35532208 | First treatment with inhaled corticosteroids and the prevention of admissions to hospital for asthma |
| Q45183030 | Fluticasone improves pulmonary function in children under 2 years old with risk factors for asthma |
| Q44016402 | Fluticasone inhibits the progression of allergen-induced structural airway changes |
| Q74776596 | Fluticasone propionate 50 micrograms BID versus 100 micrograms BID in the treatment of children with persistent asthma. Fluticasone Propionate Study Group |
| Q35532625 | Fluticasone propionate 750 micrograms/day versus beclomethasone dipropionate 1500 micrograms/day: comparison of efficacy and adrenal function in paediatric asthma |
| Q74590564 | Focusing on childhood asthma: the childhood asthma management program (CAMP) |
| Q33807137 | For and against. Should steroids be the first line treatment for asthma? |
| Q41072746 | Glucocorticoids and growth in asthmatic children |
| Q41813112 | Glutaric aciduria and suspected child abuse |
| Q52017676 | Growth during Early Childhood in Asthmatic Children: Relation to Inhalation Steroid Dose and Clinical Severity Score |
| Q74449900 | Growth in asthmatic children treated with fluticasone propionate. Fluticasone Propionate Asthma Study Group |
| Q34403679 | Growth suppression by glucocorticoid therapy |
| Q36671746 | Guideline-defining asthma clinical trials of the National Heart, Lung, and Blood Institute's Asthma Clinical Research Network and Childhood Asthma Research and Education Network |
| Q24799279 | Identification of adults with symptoms suggestive of obstructive airways disease: Validation of a postal respiratory questionnaire |
| Q35183548 | Identifying the child in need of asthma therapy |
| Q40878733 | Immunologic basis of chronic allergic diseases: clinical messages from the laboratory bench |
| Q35878513 | Impact of inhaled corticosteroids and leukotriene receptor antagonists on airway remodeling |
| Q40824465 | Inflammatory mechanisms in childhood asthma |
| Q33664193 | Inhaled Corticosteroids |
| Q33851527 | Inhaled and nasal corticosteroids: safety aspects |
| Q34547011 | Inhaled corticosteroid effects on bone metabolism in asthma and mild chronic obstructive pulmonary disease |
| Q73029002 | Inhaled corticosteroid therapy for asthma: therapeutic and toxic potentials |
| Q42415199 | Inhaled corticosteroid therapy in children: an assessment of the potential for side effects |
| Q33860023 | Inhaled corticosteroid therapy in newly detected mild asthma |
| Q36183898 | Inhaled corticosteroids and decline of lung function in community residents with asthma |
| Q77226123 | Inhaled corticosteroids and growth |
| Q34267148 | Inhaled corticosteroids as first-line therapy for asthma. Why they work--and what the guidelines and evidence suggest |
| Q35135367 | Inhaled corticosteroids in childhood asthma: long-term effects on growth and adrenocortical function. |
| Q36831058 | Inhaled corticosteroids in children with asthma: pharmacologic determinants of safety and efficacy and other clinical considerations |
| Q24194852 | Inhaled corticosteroids in children with persistent asthma: effects on growth |
| Q38287831 | Inhaled corticosteroids in children with persistent asthma: effects on growth. |
| Q38203392 | Inhaled corticosteroids in children: effects on bone mineral density and growth |
| Q24246224 | Inhaled corticosteroids versus sodium cromoglycate in children and adults with asthma |
| Q48423257 | Inhaled fluticasone propionate delivered by means of two different multidose powder inhalers is effective and safe in a large pediatric population with persistent asthma |
| Q36913007 | Insights into early treatment of mild asthma: do inhaled corticosteroids make a difference? |
| Q33835037 | Interaction between the growing lung and asthma: role of early intervention |
| Q41385582 | Intratracheal Administration of Budesonide/Surfactant to Prevent Bronchopulmonary Dysplasia |
| Q36636416 | Is there a best outcome measurement for patients with asthma? |
| Q50663158 | Issues and unmet needs in pediatric asthma. |
| Q33834984 | Issues in understanding childhood asthma. |
| Q77178360 | Leukotriene modifiers: what is their position in asthma therapy? |
| Q35627925 | Long-acting beta2-agonists: comparative pharmacology and clinical outcomes |
| Q73085804 | Long-term management of asthma |
| Q44173319 | Long-term outcomes in paediatric asthma |
| Q45258988 | Long-term safety of once-daily budesonide in patients with early-onset mild persistent asthma: results of the Inhaled Steroid Treatment as Regular Therapy in Early Asthma (START) study |
| Q37778126 | Long-term studies of the natural history of asthma in childhood |
| Q73435576 | Longitudinal growth in infants and young children treated with budesonide inhalation suspension for persistent asthma |
| Q44388193 | Low-dose budesonide for asthma |
| Q74215781 | Low-dose inhaled budesonide once or twice daily for 27 months in children with mild asthma |
| Q35143482 | Management of asthma in adults: current therapy and future directions |
| Q34929559 | Management of asthma in young children |
| Q35563600 | Measures for detecting systemic bioactivity with inhaled and intranasal corticosteroids |
| Q36825039 | Mild asthma: an expert review on epidemiology, clinical characteristics and treatment recommendations. |
| Q36930535 | Modeling asthma exacerbations through lung function in children |
| Q43547471 | Mometasone furoate: efficacy and safety in moderate asthma compared with beclomethasone dipropionate |
| Q33914371 | Montelukast: a review of its therapeutic potential in persistent asthma |
| Q31448541 | Montelukast: data from clinical trials in the management of asthma |
| Q51694110 | National study of asthma quality of life--application of the Asthma Quality of Life Questionnaire (AQLQ-M) by Marks in the Portuguese population. |
| Q35183536 | Natural history of asthma |
| Q33835032 | Natural history of chronic asthma and its long-term effects on pulmonary function |
| Q74215769 | Nosing out the future asthmatic? |
| Q44013886 | Once-daily administration of budesonide Turbuhaler was as effective as twice-daily treatment in patients with mild to moderate persistent asthma |
| Q43655195 | Once-daily budesonide inhalation powder (Pulmicort Turbuhaler) maintains pulmonary function and symptoms of asthmatic children previously receiving inhaled corticosteroids |
| Q41693586 | Once-daily budesonide inhalation suspension for the treatment of persistent asthma in infants and young children |
| Q43841704 | Once-daily budesonide inhalation suspension in infants and children < 4 and > or = 4 years of age with persistent asthma |
| Q33860037 | Once-daily inhaled corticosteroids in children with asthma: dry powder inhalers |
| Q43819600 | One-year treatment with different dosing schedules of fluticasone propionate in childhood asthma. Effects on hyperresponsiveness, lung function, and height |
| Q30579833 | Options for bronchodilation in children: can we rely on adult data? |
| Q35801421 | Oral corticosteroid-sparing effects of inhaled corticosteroids in the treatment of persistent and acute asthma |
| Q39432624 | Pharmacologic therapy for asthma. |
| Q54129342 | Pharmacology of corticosteroids. |
| Q24678822 | Pharmacotherapy and airway remodelling in asthma? |
| Q33805187 | Pharmacotherapy of asthma in children, with special reference to leukotriene receptor antagonists |
| Q35113606 | Pharmacotherapy of patients with mild persistent asthma: strategies and unresolved issues |
| Q34300554 | Phenotype specific treatment of asthma in childhood |
| Q35595099 | Preclinical properties of budesonide: translation to the clinical setting |
| Q39952222 | Prescription habits for preventative medications among pediatric emergency department physicians at an inner-city teaching hospital. |
| Q33821254 | Prognostic factors for the outcome of childhood asthma in adolescence |
| Q35718674 | Progress in the management of childhood asthma |
| Q44803819 | Progression of asthma measured by lung function in the childhood asthma management program |
| Q33597152 | Prospects for preventing asthma |
| Q47320142 | Quantification of IgE antibodies simplifies the classification of allergic diseases in 4-year-old children. A report from the prospective birth cohort study--BAMSE. |
| Q44164456 | Randomized controlled trial of fluticasone in preschool children with intermittent wheeze |
| Q41669268 | Rapid onset of control with budesonide Turbuhaler in patients with mild-to-moderate asthma |
| Q52208481 | Recognizing early asthma. |
| Q33753149 | Recurrent wheezing in infants and young children: a perspective |
| Q74300207 | Regional variation in the diagnosis of asthma among preschool-age children |
| Q41611862 | Relationships between duration of asthma and asthma severity among children in the Childhood Asthma Management Program (CAMP) |
| Q46392098 | Review of prescribed treatment for children with asthma: Author’s reply |
| Q28071831 | Revisiting early intervention in adult asthma |
| Q34246831 | Risk factors for the persistence of respiratory symptoms in childhood asthma |
| Q34533879 | Role of budesonide inhalation suspension in children with asthma |
| Q53209253 | Role of neutrophils in persistent airway obstruction due to refractory asthma. |
| Q37353978 | Safety and efficacy of inhaled corticosteroids (ICS) in children with asthma |
| Q51237805 | Safety and tolerability of inhaled budesonide in children in the Steroid Treatment As Regular Therapy in early asthma (START) trial. |
| Q43655201 | Safety of inhaled corticosteroid therapy in young children with asthma |
| Q34523194 | Safety of inhaled corticosteroids in children |
| Q44474641 | Safety of nasal budesonide in the long-term treatment of children with perennial rhinitis |
| Q81301079 | Safety of sublingual-swallow immunotherapy in children aged 3 to 7 years |
| Q74098152 | Salmeterol/fluticasone propionate (50/100 microg) in combination in a Diskus inhaler (Seretide) is effective and safe in children with asthma |
| Q56764833 | Secondary prevention of asthma by the use of Inhaled Fluticasone propionate in Wheezy INfants (IFWIN): double-blind, randomised, controlled study |
| Q46460702 | Sex-specific effects of asthma on pulmonary function in children |
| Q44713535 | Simultaneously evaluating the effects of one-week fluticasone propionate inhalation therapy on lung ventilation and permeability in children with asthma |
| Q84987098 | Spirometry Use Among Pediatric Primary Care Physicians |
| Q34340389 | Step one for asthma treatment: Beta2-agonists or inhaled corticosteroids? |
| Q33543636 | Stressors and concerns in teen asthma |
| Q33835017 | Structural consequences of airway inflammation in asthma |
| Q50853141 | Symptoms and pulmonary function in asthma. |
| Q57072321 | The Childhood Asthma Management Program (CAMP) |
| Q40826507 | The Darlington and Northallerton Prospective Asthma Study: best function predicts mortality during the first 10 years |
| Q44622681 | The Effects of One-Week Fluticasone Propionate Inhalation Therapy for Tc-99m DTPA Radioaerosol Distribution in Asthma of Children: A Preliminary Report |
| Q60958568 | The Protective Effects of 2,3,5,4'-Tetrahydroxystilbene-2--β-d-Glucoside in the OVA-Induced Asthma Mice Model |
| Q37973265 | The actual role of sodium cromoglycate in the treatment of asthma--a critical review |
| Q36156960 | The challenge of mild persistent asthma |
| Q40849767 | The down-side of early intervention with inhaled corticosteroids |
| Q43465055 | The early course of newly diagnosed asthma |
| Q33835052 | The effects of cromolyn sodium and nedocromil sodium in early asthma prevention |
| Q41113706 | The efficacy of inhaled disodium cromoglycate and glucocorticoids |
| Q35595080 | The impact of budesonide and other inhaled corticosteroid therapies in the management of asthma in children and adults |
| Q37603983 | The impact of peer support and mp3 messaging on adherence to inhaled corticosteroids in minority adolescents with asthma: a randomized, controlled trial |
| Q35169765 | The influence of inhaler selection on efficacy of asthma therapies |
| Q43713633 | The inhaled Steroid Treatment as Regular Therapy in early asthma (START) study: rationale and design |
| Q35096906 | The inhalers of the future? A review of dry powder devices on the market today |
| Q40824457 | The long-term influence of therapeutic interventions in asthma with emphasis on inhaled steroids and early disease |
| Q51700242 | The myth of mild asthma. |
| Q53520782 | The natural history of adult asthma: what do we know? |
| Q35716906 | The role of budesonide in adults and children with mild-to-moderate persistent asthma |
| Q41151318 | The role of corticosteroids in respiratory diseases of children |
| Q35754077 | The use of inhaled corticosteroids for persistent asthma in infants and young children |
| Q34561888 | The use of inhaled corticosteroids in children with asthma |
| Q45274547 | The use of sterically stabilized liposomes to treat asthma |
| Q37550543 | Therapeutic management of allergic diseases. |
| Q51649769 | Toward Asthma Prevention — Does All That Really Matters Happen before We Learn to Read? |
| Q47845672 | Towards improving the accuracy of diagnosing asthma in early childhood. |
| Q47424894 | Trajectory of spirometric and exhaled nitric oxide measurements in Chinese schoolchildren with asthma. |
| Q35189203 | Treating the wheezing infant |
| Q41722672 | Treatment of childhood asthma. Options and rationale for inhaled therapy |
| Q35544014 | Treatment of childhood asthma: how do the available options compare? |
| Q64107391 | Two Sides of the Same Coin?-Treatment of Chronic Asthma in Children and Adults |
| Q44334519 | Urinary leukotriene E(4), eosinophil protein X, and nasal eosinophil cationic protein are not associated with respiratory symptoms in 1-year-old children |
| Q32059841 | Use of cohorts with extensive longitudinal data in investigating the molecular genetics of asthma |
| Q35279564 | Using child reported respiratory symptoms to diagnose asthma in the community |
| Q40419923 | Variability analysis of oscillatory airway resistance in children |
| Q33847383 | What is new in asthma: new dry powder inhalers |
| Q53875270 | Wheezing in early life and asthma at school age: predictors of symptom persistence. |
| Q33860271 | Why does airway inflammation persist? Is it failure to treat early? |
| Q77908757 | [Airway remodelling in asthma] |
| Q80430977 | [Asthma treatment in childhood: from guidelines to practice] |
| Q79487576 | [Characteristics of mild asthma: clinical signs and medication use. Position statement of the Mild Asthma Working Group (174)] |
| Q73878681 | [Inhaled glucocorticoids and their effects on growth in children] |
| Q77681673 | [What is new in pediatric pneumology?] |
| Q79796761 | [Wheezing in infants and toddlers: new insights] |